Trending...
- MetaSwap Exchange Rolls Out Multilingual Access System to Enhance Global User Experience
- Last Call - Submit Your Proposal for the 2025 OpenSSL Conference in Prague
- Experience Trembling Firsthand with the New AgeMan® Tremor Simulator
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Bolt To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Bolt between February 5, 2021 and May 14, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/BOLT.
NEW YORK, July 19, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bolt Biotherapeutics, Inc. ("Bolt" or the "Company") (NASDAQ: BOLT) and reminds investors of the September 3, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
More on Nyenta.com
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) BDC-1001 was less effective than the Company had represented to investors and was in fact unlikely to meet its pre-defined success criteria; (2) accordingly, Defendants overstated the clinical and/or commercial prospects of Bolt's product pipeline, on which the Company primarily relies to sustain its business model; (3) all of the foregoing subjected the Company to a heightened risk of disruptive leadership transitions and substantial workforce reduction; and (4) as a result, the Company's public statements were materially false and misleading at all relevant times.
On May 14, 2024, Bolt announced in a press release that the Company would "cease further development of trastuzumab imbotolimod (BDC-1001)," Bolt's lead asset, "and reduce workforce by approximately 50%." Following Bolt's announcement, multiple analysts downgraded the Company's stock.
On this news, Bolt's stock price fell $0.49 per share, or more than 37.12%, to close at $00.83 per share on May 15, 2024.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
More on Nyenta.com
Faruqi & Faruqi, LLP also encourages anyone with information regarding Bolt's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Bolt class action, go to www.faruqilaw.com/BOLT or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
SOURCE Faruqi & Faruqi, LLP
If you purchased or acquired securities in Bolt between February 5, 2021 and May 14, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/BOLT.
NEW YORK, July 19, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bolt Biotherapeutics, Inc. ("Bolt" or the "Company") (NASDAQ: BOLT) and reminds investors of the September 3, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
More on Nyenta.com
- ZeOmega and MVP Health Care Partner to Advance Health Outcomes and Member Experience
- Keebos Launches New Universal Pearl Strap That Attaches to Any Phone Case
- RH7 Sports Signs World-Class Hurdler Tonea Marshall, Strengthening Its Roster of Women Athletes
- Specialized Lead Generation Service for SEO Companies
- Work 365 Launches Certified Provider Integration (CPI) Program to Help Distributors and CSPs Navigate Microsoft's Evolving Ecosystem
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) BDC-1001 was less effective than the Company had represented to investors and was in fact unlikely to meet its pre-defined success criteria; (2) accordingly, Defendants overstated the clinical and/or commercial prospects of Bolt's product pipeline, on which the Company primarily relies to sustain its business model; (3) all of the foregoing subjected the Company to a heightened risk of disruptive leadership transitions and substantial workforce reduction; and (4) as a result, the Company's public statements were materially false and misleading at all relevant times.
On May 14, 2024, Bolt announced in a press release that the Company would "cease further development of trastuzumab imbotolimod (BDC-1001)," Bolt's lead asset, "and reduce workforce by approximately 50%." Following Bolt's announcement, multiple analysts downgraded the Company's stock.
On this news, Bolt's stock price fell $0.49 per share, or more than 37.12%, to close at $00.83 per share on May 15, 2024.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
More on Nyenta.com
- Boston Globe Media Celebrates Prestigious Journalism Award Wins Across The Organization
- Two Financial Legends, Joseph Jordan and Tom Hegna Team Up on the Podcast "Financial Freedom with Tom Hegna"
- International Bestselling Author Robert Rolih Joins Tom Hegna on "Financial Freedom with Tom Hegna"
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Designer Brands Inc. - DBI
- NEW "Summer Sip" Event Comes to City Winery Hudson Valley
Faruqi & Faruqi, LLP also encourages anyone with information regarding Bolt's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Bolt class action, go to www.faruqilaw.com/BOLT or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
SOURCE Faruqi & Faruqi, LLP
Filed Under: Business
0 Comments
Latest on Nyenta.com
- COZYINN Launches Foldable 2-in-1 Walking Pad & Treadmill — High Performance Meets Compact Living
- Perbelle Cosmetics Announces CC Cream Bundle-Packs with Tiered Discounts Tailored for Every Customer
- Revize Unleashes a Cutting-Edge Web Experience for New York Community
- WMBT Exchange Launches Trading Insights Module to Empower User Decision-Making
- Stagwell's (NASDAQ: STGW) PRophet Expands Global Partnership with Hootsuite to Power the Future of Social and Media Intelligence through AI USA - English USA - English
- The White Thobe for Men: A Reflection of Sunnah and Elegance
- Bay Ridge Honda Launches Employee Purchase Program
- National Online Course Offers K–12 Educators Training Empowering students through Media Decoding
- PUSHERMAN- – Best Feature Documentary Official Winner at NYC and London Festivals
- Female Motorsports Sponsorship & Expansion; Acquisition Agreement of UAE-Based Sports Incubator by Online Lottery & Sports Game Provider: Lottery.com
- SupplyHouse Named One of Fortune's Best Workplaces in New York in 2025
- Kosinima, Inc. Unveils Third Cohort Of Grantees, Expanding Global Footprint For Black Filmmakers
- Global Court Momentum Builds Against Forced Psychiatry; CCHR Urges U.S. Reform
- ¡Buenos Días, USA!AIRE Radio Networks Announces the Syndication of El Show de Raúl Brindis
- Integris Composites Joins Paris Air Show at USA Pavilion
- Cheryl Hines' Trailer PROWLING to Sardinia
- Top 5 Myths About Dental Implants – Debunked by a Webster, NY Dentist
- Honoring Black History, Culture, and Community in Fall River
- Token-Operated Sake Service Opens at Tobu Nikko Station
- Kola Ewousho's new book, "Behind Enemy Lines," inspires strong Christian faith